Bicycle Therapeutics plc

BCYC ·Healthcare, Drug Manufacturers - General, United Kingdom
Financial Statements Income Statement
Annual Quarterly

Income Statement

Line Item FY2017
Revenue $2.1M
Cost of Revenue
Gross Profit
Gross Margin
Operating Expenses
Research & Development $11.9M
SG&A Expense $6.4M
Operating Income $-16.2M
Operating Margin -787.0%
Interest Expense
Pretax Income $-16.3M
Income Tax Expense $-23.0K
Net Income $-16.3M
Net Margin -789.3%
EPS (Basic) $-48.81
EPS (Diluted) $-48.81
Shares Outstanding (Basic)
Shares Outstanding (Diluted)
Dividends Per Share
← Newer Page 2 of 2 Older →